PL
ASND icon

Perpetual Ltd’s Ascendis Pharma A/S ASND Stock Holding History

Perpetual Ltd’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-100,638
Closed -$23M – 423
2026
Q1 		$23M Buy
+100,638
New +$22.6M 0.35% 78

Other funds holding ASND

AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return
SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
SAM
Synergy Asset Management Vancouver, Washington $1.06B AUM 36.26% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
HJIM
Henry James International Management New York $334M AUM 49.44% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return
MIF
Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return
FISPB
Fideuram - Intesa Sanpaolo Private Banking Turin $3.33B AUM

Perpetual Ltd's ASND Position: Q2 2026 in Review

Perpetual Ltd sold out of Ascendis Pharma A/S (ASND) in Q2 2026, closing a stake of 100,638 shares — an estimated $23M sold.

Perpetual Ltd first reported a position in ASND in Q1 2026 and held it in 1 quarter. The position peaked at $23M in Q1 2026. 47 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

  • Perpetual Ltd reported no remaining Ascendis Pharma A/S position as of Q2 2026 after selling out during the quarter.
  • Perpetual Ltd sold 100,638 Ascendis Pharma A/S shares in Q2 2026, an estimated $23M.
  • Perpetual Ltd first reported a position in Ascendis Pharma A/S in Q1 2026 and held it in 1 quarter.
  • Perpetual Ltd's Ascendis Pharma A/S position peaked at $23M in Q1 2026.
  • 47 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Perpetual Ltd's 13F filing for Q2 2026, filed 15 Jul 2026.